10-Q: Quarterly report

SECMay 13 04:07 · Announcements

Trading Halt: Halt Status Updated at 7:30:00 AM ET: Quotation Resumption: News and Resumption Times

BenzingaApr 27 19:30

Trading Halt: Halted at 6:55:00 A.m. ET - Trading Halt: Halt News Pending

BenzingaApr 27 18:55

10-K: FY2025 Annual Report

SECMar 19 04:08 · Announcements

XOMA Royalty Corporation's 8.625% Cumulative Perpetual Preferred Series A (XOMAP.US) is scheduled to release its earnings report before the market opens on March 18.

XOMA Royalty Corporation’s 8.625% Cumulative Perpetual Preferred Series A (XOMAP.US) is scheduled to release its earnings report before the market opens on March 18. Investors are advised to stay tuned. What about its previous performance? XOMA Royalty Corporation’s 8.625% Cumulative Perpetual Preferred Series A (XOMAP.US) reported operating revenue of $532,000 and net profit of $14,051,000 in Q3 2025.

Futu NewsMar 12 20:45

GLP-1 Spillover, AI Empowerment... Could Biopharmaceuticals Become the 'Alternative' to Tech Stocks in 2026?

Citi noted that the indications for GLP-1 are expanding from weight management to cardiovascular and nervous system applications, alongside an anticipated expansion of Medicare coverage and the launch of Eli Lilly and Co’s oral medication orforglipron; AI is fully delivering cost and efficiency gains across R&D, production, and clinical stages; in addition, the DTP (Direct-to-Patient) model is reshaping distribution channels. As a result, the industry’s overall profitability and innovation conversion efficiency are significantly improving.

wallstreetcnJan 7 16:43